Non-ergot dopamine agonist

Pramipexole

Pramipexole is a non-ergot dopamine agonist; its US label lists Parkinson's disease and moderate-to-severe primary restless legs syndrome, and a half-life of about 8 hours in young healthy volunteers.1

Moderate evidenceGet the app

Level after one dose

Pramipexole after one dose: 50% at ~8 h, 25% at 16 h, 12.5% at 24 h.

Drawn from the half-life in the app's model, ~8 h. The model's figures

Pramipexole is a non-ergot dopamine agonist. The US prescribing label for pramipexole dihydrochloride tablets lists two indications, Parkinson's disease and moderate-to-severe primary restless legs syndrome (RLS), and gives its initial US approval year as 1997.1 The app files it as a dopamine agonist under post-cycle therapy and ancillary compounds, with the synonyms prami and mirapex.

The trials summarised below were run in people with Parkinson's disease or RLS, apart from two studies in healthy volunteers, of 12 and 16 people, that measured hormone levels.2,3 A search of PubMed on 16 November 2026 for pramipexole in the title or summary text returned 1,677 records. The same search combined with nandrolone, trenbolone or 19-nor returned 0 records, and combined with bodybuilding, post-cycle, anabolic or steroid it returned 2 records, whose titles concern a mouse model of traumatic stress and a case report of limb dystonia in Parkinson's disease.

The label describes pramipexole as a non-ergot dopamine agonist “with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes.”1 For Parkinson's disease the label says the mechanism “is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum,” and that the relevance of D3 receptor binding in Parkinson's disease is unknown. For RLS it also says the precise mechanism is unknown.1

On prolactin, the label's section on lactation says “inhibition of lactation is expected because pramipexole inhibits secretion of prolactin in humans.”1 Schilling and colleagues, writing from the Human Pharmacology Centre of Boehringer Ingelheim KG in Clinical Pharmacology and Therapeutics in 1992, reported that single oral doses of 0.1, 0.2 and 0.3 mg “decreased serum prolactin levels in a dose-dependent manner” in 12 healthy volunteers.2

3

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~8 h
Bioavailability
90%
Typical dose
0.125–0.5 mg/day
Route
Oral
Time to peak
~2 h
Table 3.1Pharmacokinetics6 rows
ParameterApp figureFigure in the source
Half-life~8 hoursAbout 8 hours in young healthy volunteers and about 12 hours in elderly volunteers; the geriatric section gives an increase in elimination half-life from approximately 8.5 hours to 12 hours.1
Bioavailability~90%Absolute bioavailability greater than 90%.1
Time to peak~2 hoursPeak concentrations in approximately 2 hours; the time of maximum concentration is increased by about 1 hour with a meal, and food does not affect the extent of absorption.1
Duration of activity~18 hoursThe label text holds no duration-of-activity figure.
RouteOralTablets of 0.125, 0.25, 0.5, 0.75, 1 and 1.5 mg.1
Typical dose0.125 to 0.5 mg/dayThe label's Parkinson's maintenance range is 1.5 to 4.5 mg/day in three divided doses; its RLS schedule runs from 0.125 to 0.5 mg once daily.1

The label says pramipexole “displays linear pharmacokinetics over the clinical dosage range” and that steady-state concentrations “are achieved within 2 days of dosing.”1 Its volume of distribution is about 500 L and it is about 15% bound to plasma proteins. It is metabolized only to a negligible extent, and 90% of a dose is recovered in urine, almost all as unchanged drug, with a renal clearance of approximately 400 mL/min.1

By group, the label reports clearance about 30% lower in women than in men, a difference it attributes to body weight, with no difference in half-life between the sexes. Clearance was about 75% lower in severe renal impairment (creatinine clearance approximately 20 mL/min) and about 60% lower in moderate impairment (approximately 40 mL/min). Cimetidine caused a 50% increase in pramipexole AUC and a 40% increase in half-life in 12 volunteers.1

The chart below is the app's own one-compartment model, using the app's half-life of 8 hours and time to peak of 2 hours, drawn at once-daily and three-times-daily schedules that the label gives.1 It is a model, not measured concentrations.

Level over 4 days

Interval between doses

Level, as a share of the peak after one 0.5 mg dose

As studied: once daily1, three times a day1.

An illustration from a pharmacokinetic model using a half-life of 8 hours. It is not a measured level or a suggested dose.

4

Human studies

Table 4.1Human studies9 rows
Study and yearDesignPeopleDose and lengthMain result
Parkinson Study Group, JAMA 19974Randomised, double-blind, placebo-controlled, multicentre dose-ranging; the record lists U.S. Public Health Service research support264 people with early Parkinson's disease, not requiring or receiving levodopa or other dopamine agonists1.5, 3.0, 4.5 or 6.0 mg/d or placebo, 10 weeksTotal UPDRS improved by 5.9 to 7.0 units on pramipexole against 0.9 on placebo (P<.005 for each). Completion on the assigned dose: 98% on placebo, and 81%, 92%, 78% and 67% on the four doses. The record reports a trend toward increased frequency of adverse experiences, particularly somnolence, in the 6.0 mg/d group.
US label, early Parkinson's disease study1Double-blind, placebo-controlled, parallel; sponsor not named in the label text335 people with early Parkinson's disease, no levodopaTitrated to a maximally tolerated dose, no higher than 4.5 mg/day in three divided doses; 6-month maintenanceUPDRS part II improved by 1.9 on pramipexole and -0.4 on placebo, and part III by 5.0 and -0.8, both differences statistically significant.
US label, advanced Parkinson's disease study1Double-blind, placebo-controlled, parallel; sponsor not named in the label text360 people with advanced Parkinson's disease on levodopa, mean disease duration 9 yearsTitrated to a maximally tolerated dose, no higher than 4.5 mg/day in three divided doses; 6-month maintenanceUPDRS part II improved by 2.7 against 0.5 on placebo and part III by 5.6 against 2.8; mean off time was 4 hours a day on pramipexole against 6 on placebo; levodopa was reduced in 76% against 54%.
Holloway and colleagues, Arch Neurol 2004 (CALM-PD)5Randomised, double-blind, parallel-group, 22 sites; pramipexole against carbidopa/levodopa301 people with early Parkinson's disease needing dopaminergic therapyPramipexole 0.5 mg three times a day or carbidopa/levodopa 25/100 mg three times a day, followed to 48 monthsDyskinesias 24.5% on pramipexole against 54% on levodopa (hazard ratio 0.37, P<.001); freezing 25.3% on levodopa against 37.1% on pramipexole (P=.01); UPDRS improved more on levodopa (P=.003).
Parkinson Study Group CALM cohort, Arch Neurol 20096Open extended follow-up of CALM-PD; initial pramipexole or initial levodopa, then open-label levodopa222 of the 301 people who consented to extended follow-upMean follow-up 6.0 yearsBetween initial pramipexole and initial levodopa, self-reported disability scores were similar (79.9 against 82.5, P = .19); motor complications 50.0% against 68.4% (P = .002); Epworth Sleepiness Scale 11.3 against 8.6 (P < .001); total UPDRS change did not differ significantly (2.4 against 0.5, P = .11).
Barone and colleagues, Lancet Neurology 20107Randomised, double-blind, placebo-controlled, 76 centres in 12 European countries and South Africa; the record lists the publication type Research Support, Non-U.S. Gov't and names no funder296 randomised, 287 analysed (139 pramipexole, 148 placebo), mild-to-moderate Parkinson's disease with depressive symptoms0.125 to 1.0 mg three times per day, 12 weeksBeck depression inventory fell by an adjusted mean 5.9 on pramipexole against 4.0 on placebo (difference 1.9, 95% CI 0.5-3.4; p=0.01); UPDRS motor score decreased by an adjusted mean 4.4 against 2.2 (difference 2.2, 95% CI 0.7-3.7; p=0.003). Adverse events: 105 of 144 on pramipexole, 101 of 152 on placebo.
US label, RLS studies 1 and 21Four double-blind, placebo-controlled trials; study 1 fixed-dose, study 2 randomised withdrawal; sponsor not named in the label text344 people in study 1; 147 randomised in study 2 after 6 months open labelStudy 1: 0.25, 0.5 or 0.75 mg once daily, 12 weeks. Study 2: continued pramipexole or placebo, 12 weeksStudy 1: IRLS score -13.6 on pramipexole against -9.4 on placebo, with no clear dose-response. Study 2: 85% on placebo had failed treatment against 21% on pramipexole.
Allen and colleagues, N Engl J Med 20148Randomised, double-blind, 52 weeks; pregabalin against pramipexole and placebo; funded by Pfizer719 people with RLSPregabalin 300 mg, pramipexole 0.25 or 0.5 mg a day, or 12 weeks of placebo then active treatment; 52 weeksOver 12 weeks pregabalin beat placebo on the IRLS scale by 4.5 points (P<0.001). Augmentation over 40 or 52 weeks: pregabalin 2.1%, pramipexole 0.25 mg 5.3% (P=0.08 against pregabalin), pramipexole 0.5 mg 7.7% (P=0.001 against pregabalin).
Schilling and colleagues, Clin Pharmacol Ther 19922Randomised, double-blind, crossover; no funding stated in the record12 healthy volunteersSingle oral doses of 0.1, 0.2 and 0.3 mg or placebo, 24 hoursSerum prolactin fell dose-dependently, maximum after 2 to 4 hours; growth hormone rose dose-dependently, significant only at 2 hours.

Deeper analysis: pramipexole against levodopa in CALM-PD

Holloway (University of Rochester) and colleagues of the Parkinson Study Group, Archives of Neurology, 2004, randomised 301 people with early Parkinson's disease at 22 academic clinics in the United States and Canada, 151 to pramipexole 0.5 mg three times a day and 150 to carbidopa/levodopa 25/100 mg three times a day, each with a placebo for the other, and observed them until August 2001.5 After the first 10 weeks of escalation, investigators could add open-label levodopa or other antiparkinsonian medication.5

The main outcomes were the time to the first dopaminergic complication (wearing off, dyskinesias, on-off fluctuations, freezing), rating-scale changes and adverse events. Wearing off occurred in 47% against 62.7% (hazard ratio 0.68, P=.02) in the pramipexole and levodopa groups, and by 48 months disabling dyskinesias were uncommon and did not differ significantly between groups. The mean improvement in total UPDRS score from baseline to 48 months was greater in the levodopa group than in the pramipexole group (2 ± 15.4 points against -3.2 ± 17.3, P=.003). Somnolence (36% against 21%, P=.005) and edema (42% against 15%, P<.001) were more common on pramipexole, and quality-of-life changes did not differ between groups.5

In the group's extended follow-up (222 of the 301 people, mean 6.0 years), self-reported disability scores were similar, motor complications remained less common in the initial pramipexole group (50.0% against 68.4%), and Epworth Sleepiness Scale scores were higher in that group (11.3 against 8.6).6 The authors conclude that “levodopa and pramipexole both appear to be reasonable options as initial dopaminergic therapy for Parkinson disease, but they are associated with different efficacy and adverse-effect profiles.”5 The 2004 PubMed record lists U.S. Public Health Service research support (two grants listed under NCRR); the 2009 record lists the publication type Research Support, Non-U.S. Gov't and no grant. Neither record carries an author disclosure statement or a limitations section.5,6

Deeper analysis: pregabalin against pramipexole in restless legs syndrome

Allen and colleagues, with affiliations at Johns Hopkins University, Pfizer, the Sleep Research Institute in Madrid, Tampere University Hospital and Massachusetts General Hospital, reported in the New England Journal of Medicine in 2014 a 52-week randomised, double-blind trial in which 719 people with RLS received pregabalin 300 mg a day (182), pramipexole 0.25 mg (178), pramipexole 0.5 mg (180) or placebo (179).8 The record's funding line reads “Funded by Pfizer,” and four authors are listed at Pfizer Global Research and Development.8

The primary analyses compared pregabalin with placebo over 12 weeks and augmentation rates with pregabalin and pramipexole over 40 or 52 weeks. Pregabalin lowered the International RLS scale score by 4.5 points more than placebo (P<0.001), and 71.4% on pregabalin against 46.8% on placebo were much or very much improved. Augmentation was 2.1% with pregabalin, 5.3% with pramipexole 0.25 mg (P=0.08 against pregabalin) and 7.7% with pramipexole 0.5 mg (P=0.001 against pregabalin). There were six cases of suicidal ideation on pregabalin, three on pramipexole 0.25 mg and two on 0.5 mg. The record's results give no pramipexole against placebo score comparison, and the PubMed record states no limitations and no author disclosures.8

Deeper analysis: hormone effects in healthy volunteers

Schilling, Adamus and Palluk (Human Pharmacology Centre, Boehringer Ingelheim KG, Germany), Clinical Pharmacology and Therapeutics, 1992, gave 12 healthy volunteers single oral doses of 0.1, 0.2 and 0.3 mg or placebo in a randomised, double-blind crossover study and followed them for 24 hours. Serum prolactin fell dose-dependently with a maximum effect after 2 to 4 hours. Growth hormone was “dose-dependently increased; however, this effect was only significant 2 hours after drug administration.” The authors also report a slight increase in serum cortisol and a slight decrease in thyrotropin, and say the compound was well tolerated. The record states no funding and no limitations.2

Samuels and colleagues (University of Nottingham), Journal of Psychopharmacology, 2006, gave 16 healthy males pramipexole 0.5 mg, modafinil 200 mg or both against placebo and reported that pramipexole reduced alertness, increased heart rate, reduced prolactin and thyroid stimulating hormone, and increased growth hormone.3 The PubMed record states no funding.3

5

Doses reported in studies and on labels

Table 5.1Doses reported in studies and on labels8 rows
SourceDoseFrequencyLength
US label, Parkinson's disease schedule10.125 mg per dose in week 1, rising to 1.5 mg per dose in week 7 (0.375 to 4.5 mg/day)Three times a dayWeekly steps, not more often than every 5 to 7 days; maintenance range 1.5 to 4.5 mg/day
US label, RLS schedule10.125, 0.25 or 0.5 mg; the label says there is no evidence that 0.75 mg gives additional benefit beyond 0.5 mgOnce daily, 2 to 3 hours before bedtimeSteps every 4 to 7 days
Parkinson Study Group, 19971.5, 3.0, 4.5 or 6.0 mgPer day10 weeks
Holloway and colleagues, 20040.5 mgThree times a dayUp to 48 months
Barone and colleagues, 20100.125 to 1.0 mgThree times per day12 weeks
Allen and colleagues, 20140.25 or 0.5 mgPer day52 weeks
Schilling and colleagues, 19920.1, 0.2 or 0.3 mgSingle oral doseObserved over 24 hours
Samuels and colleagues, 20060.5 mgNot stated in the recordNot stated in the record

The app's typical dose range is 0.125 to 0.5 mg/day. The label gives 0.125 to 0.5 mg once daily as its RLS schedule and 1.5 to 4.5 mg/day as its Parkinson's maintenance range.1

In the label's three double-blind, placebo-controlled trials in early Parkinson's disease, nausea was reported by 28% on pramipexole against 18% on placebo, somnolence 22% against 9%, insomnia 17% against 12%, constipation 14% against 6% and dizziness 25% against 24% (388 and 235 people). About 12% of the 388 stopped because of adverse reactions against 11% of 235 on placebo.1 Hallucinations were reported in 9% (35 of 388) against 2.6% (6 of 235) in early disease, and in 16.5% (43 of 260) against 3.8% (10 of 264) in advanced disease with levodopa; the label says age appears to increase the risk.1 In the label's four trials in advanced disease with levodopa, dyskinesia was reported by 47% on pramipexole against 31% on placebo, postural hypotension by 53% against 48% and insomnia by 27% against 22%; about 12% of 260 stopped because of adverse reactions against 16% of 264 on placebo.1

In the label's pooled RLS trials (575 on pramipexole 0.125 to 0.75 mg/day, 223 on placebo), nausea was 16% against 5%, somnolence 6% against 3% and headache 16% against 15%; about 7% stopped because of adverse reactions against 5%. The label says nausea and somnolence “were generally mild and transient.”1 In the fixed-dose study, nausea was 11%, 19% and 27% at 0.25, 0.5 and 0.75 mg against 5% on placebo.1 In a 26-week RLS trial, worsening beyond untreated baseline after sudden withdrawal was reported by 10% against 2%, and augmentation by 12% against 9% on placebo; the label says the frequency and severity of augmentation and rebound after longer-term use “have not been adequately evaluated in controlled clinical trials.”1

The label warns that people treated with pramipexole “have reported falling asleep while engaged in activities of daily living, including the operation of motor vehicles which sometimes resulted in accidents,” some as late as one year after starting.1 It also lists orthostatic hypotension, intense urges to gamble, increased sexual urges, uncontrolled spending and binge eating, and symptoms reported after stopping dopamine agonists (apathy, anxiety, depression, fatigue, insomnia, sweating and pain). In its trials clinically significant orthostatic hypotension was not more frequent on pramipexole than on placebo, despite clear orthostatic effects in normal volunteers; the label says this might be explained by the conditions of the study, because patients were very carefully titrated and those with active cardiovascular disease or significant orthostatic hypotension at baseline were excluded, and that patients ordinarily require careful monitoring for signs and symptoms of orthostatic hypotension.1

Weintraub and colleagues (University of Pennsylvania and others), Archives of Neurology, 2010, a cross-sectional study of 3,090 people with treated Parkinson's disease at 46 centres, found an impulse control disorder in 13.6%: 17.1% of those on a dopamine agonist against 6.9% of those not (odds ratio 2.72, 95% CI 2.08-3.54). Frequency was 17.7% on pramipexole and 15.5% on ropinirole (odds ratio 1.22, 95% CI 0.94-1.57, P = .14). The authors say the other associated variables suggest “a complex relationship that requires additional investigation.” The PubMed record lists the publication type Research Support, Non-U.S. Gov't, no grant and no disclosure statement.9

7

Bloodwork and markers

The app lists total testosterone, free testosterone, estradiol, LH and FSH as markers for pramipexole. The label text mentions none of them, and none of the trial records summarised above reports them. The hormones the studies measured were serum prolactin, growth hormone, thyrotropin, cortisol and corticotropin in the 1992 study, and prolactin, growth hormone and thyroid stimulating hormone in the 2006 study.2,3

8

Regulatory and anti-doping status

The US label lists pramipexole for Parkinson's disease and moderate-to-severe primary RLS, with initial US approval in 1997, and states that safety and effectiveness in pediatric patients have not been established.1

The WADA 2026 Prohibited List text does not contain the name pramipexole. Its class S0, prohibited at all times in and out of competition, covers “any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use.”10

9

Storage and handling

The label gives storage at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C, and says to protect from light.1

The label says the precise mechanism in Parkinson's disease and in RLS is unknown, and that the effect of pramipexole on QTc intervals at higher exposures, from drug interactions, renal impairment or higher doses, has not been systematically evaluated.1 It also says the influence of hepatic insufficiency on pramipexole pharmacokinetics has not been evaluated.1

None of the studies summarised above concerns post-cycle therapy. The search of PubMed for pramipexole combined with nandrolone, trenbolone or 19-nor returned 0 records on 16 November 2026, and the label text gives no duration-of-activity figure, while the 1992 growth hormone rise was significant only at 2 hours.2

What is the half-life of pramipexole?

The label gives a terminal half-life of about 8 hours in young healthy volunteers and about 12 hours in elderly volunteers; the app lists about 8 hours.1 The label's geriatric section gives an increase in elimination half-life from approximately 8.5 hours to 12 hours, and says steady-state concentrations are reached within 2 days of dosing.1

What is pramipexole used for?

The US label lists pramipexole for Parkinson's disease and for moderate-to-severe primary restless legs syndrome.1 The label's trials were in those conditions, and it calls the drug a non-ergot dopamine agonist.1

How long does pramipexole take to peak?

The label gives peak concentrations in approximately 2 hours.1 It adds that taking it with a meal increases the time to maximum concentration by about 1 hour and that food does not affect the extent of absorption.1

What is the bioavailability of pramipexole?

The label gives an absolute oral bioavailability of greater than 90%; the app lists 90%.1 The label says this indicates the drug is well absorbed and undergoes little presystemic metabolism.1

Does pramipexole lower prolactin?

In 12 healthy volunteers, single oral doses of 0.1, 0.2 and 0.3 mg decreased serum prolactin in a dose-dependent manner, with a maximum effect after 2 to 4 hours.2 In 16 healthy males, 0.5 mg also reduced prolactin, and the label says pramipexole inhibits secretion of prolactin in humans.3,1

Does pramipexole raise growth hormone?

In the 1992 study of 12 healthy volunteers, serum growth hormone was dose-dependently increased, but the effect was only significant 2 hours after administration.2 In the 2006 study of 16 healthy males, 0.5 mg increased growth hormone level.3

What are the common side effects of pramipexole?

In the label's early Parkinson's disease trials, the most common adverse reactions above 5% that were numerically more frequent than placebo were nausea, dizziness, somnolence, insomnia, constipation, asthenia and hallucinations.1 In its RLS trials the most common were nausea and somnolence, with nausea 16% against 5% on placebo.1

Is pramipexole banned by WADA?

The WADA 2026 Prohibited List text does not contain the name pramipexole.10 Its class S0, prohibited at all times, covers any pharmacological substance not addressed by another section of the list and with no current approval by any governmental regulatory health authority for human therapeutic use.10

What did the 4-year trial of pramipexole against levodopa find?

In CALM-PD, 301 people with early Parkinson's disease started on pramipexole or carbidopa/levodopa, and dyskinesias occurred in 24.5% on pramipexole against 54% on levodopa.5 Freezing was more common on pramipexole (37.1% against 25.3%), the UPDRS improvement was greater in the levodopa group (P =.003), and somnolence and edema were more common on pramipexole.5

13

References

  1. PRAMIPEXOLE DIHYDROCHLORIDE tablet. Strides Pharma Science Limited. DailyMed, label text revised 08/2025. DailyMed label
  2. Schilling JC, Adamus WS, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther 1992. PMID 1350237
  3. Samuels ER, et al. Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. J Psychopharmacol 2006. PMID 16401653
  4. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997. PMID 9214527
  5. Holloway RG, et al; Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004. PMID 15262734
  6. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009. PMID 19433655
  7. Barone P, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010. PMID 20452823
  8. Allen RP, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 2014. PMID 24521108
  9. Weintraub D, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010. PMID 20457959
  10. World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List 2026. WADA list